SCHEMBL24010098

SCHEMBL24010098

COc1ccc(CS(C)(=N)=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 2/20 0.55
▸ IDO1 P14902 3/20 0.48
▸ AGXT P21549 2/20 0.48
▸ PLCG1 P19174 1/20 0.47
▸ HTT P42858 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ CYP3A4 P08684 1/20 0.47
▸ ALOX15 P16050 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ ALOX12 P18054 1/20 0.47
▸ PKM P14618 1/20 0.47
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ CA12 O43570 1/20 0.46
▸ CA1 P00915 1/20 0.46
▸ CA2 P00918 1/20 0.46
▸ CA5A P35218 1/20 0.46
▸ CA9 Q16790 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377998 0.83 APLNR (0.58) APLNRIDO1AGXTPLCG1HTT
SCHEMBL19439114 0.82 CA1 (0.53) APLNRIDO1AGXTPLCG1HTT
SCHEMBL11542032 0.82 APLNR (0.52) APLNRIDO1AGXTPLCG1HTT
SCHEMBL2717301 0.81 KMT2A (0.57) APLNRIDO1AGXTPLCG1HTT
SCHEMBL3237396 0.79 PKM (0.56) APLNRIDO1PLCG1HTTALDH1A1
SCHEMBL294919 0.79 APLNR (0.53) APLNRIDO1AGXTPLCG1HTT
SCHEMBL3237393 0.79 KMT2A (0.55) APLNRIDO1AGXTPLCG1HTT
SCHEMBL30496480 0.79 PKM (0.56) APLNRIDO1PLCG1HTTALDH1A1
SCHEMBL294920 0.78 APLNR (0.52) APLNRIDO1PLCG1HTTPKM
SCHEMBL1259871 0.78 APLNR (0.52) APLNRIDO1AGXTPLCG1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-10-10 — — US disclosed
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2023-01-05 — — US disclosed
WO-2021225969-A1 IMINO SULFANONE INHIBITORS OF ENPP1 VOLASTRA THERAPEUTICS, INC. (US) 2021-11-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780849-B2 Imino sulfanone inhibitors of ENPP1 ENPP1, ENPP3, SMPD1 APLNR 3967/4885IDO1 452/4885AGXT 3414/4885
US-20230002406-A1 IMINO SULFANONE INHIBITORS OF ENPP1 ENPP1, ENPP3, SMPD1 APLNR 3967/4885IDO1 452/4885AGXT 3414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback